ENTXW - (Entera Bio Ltd.)

ENTXWのニュース

   Entera Bio: Q2 Earnings Insights  2022/08/11 13:43:34 Benzinga
Entera Bio (NASDAQ: ENTX ) reported its Q2 earnings results on Thursday, August 11, 2022 at 06:00 AM. Here''s what investors need to know about the announcement. Earnings Entera Bio beat estimated earnings by 31.25%, reporting an EPS of $-0.11 versus … Full story available on Benzinga.com
   Entera Bio GAAP EPS of -$0.24 , revenue of $0.11M  2022/08/11 12:59:00 Seeking Alpha
Entera Bio press release (ENTX): 1H GAAP EPS of -$0.24.Revenue of $0.11M (-59.3% Y/Y).Shares +3.68% PM
   Entera Bio Provides Business Highlights and Financial Results for the Second Quarter 2022  2022/08/11 10:30:00 GlobeNewswire
JERUSALEM, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced its financial and operating results for the quarter ended June 30, 2022.
   Entera Bio Outlines Pivotal Osteoporosis Trial, Names New CEO  2022/07/18 13:11:36 Benzinga
Following its End of Phase 2 Meeting with the FDA, Entera Bio Ltd (NASDAQ: ENTX ) has designed the pivotal study for EB613 as an 18-month double-blind placebo-controlled study, followed by a 6-month open-label transition to alendronate for all patients. The study''s primary endpoint employs the Foundation for the National Institutes of Health Bone Quality Program (FNIH BQP) total hip Bone Mineral Density (BMD) as a surrogate endpoint … Full story available on Benzinga.com
   Entera Bio Announces Departure of Dr. Phillip Schwartz, the Company''s President of Research & Development to Pursue Outside Opportunities  2022/06/17 21:00:00 Benzinga
BOSTON and JERUSALEM, June 17, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX ), a leader in the development of orally delivered peptides and therapeutic proteins, today announced that Dr. Phillip Schwartz, the Company''s President of Research & Development and Founder, will resign from his current role effective July 21, 2022 to pursue other opportunities. Dr. Schwartz also stepped down from the Company''s Board of Directors, effective June 15, 2022. Dr. Schwartz''s resignation was not a result of any disagreement with the Company and Dr. Schwartz will remain as a consultant to the Company. Bringing in his expertise from various development and commercialization roles at Merck KGaA-Serono and Endo Pharmaceuticals, Dr. Schwartz was a co-founder of Entera Bio in 2009 and led the Company as Chief Executive Officer through 2019 and its IPO in 2018. "We are grateful for Phillip''s vision and leadership which have been paramount to the progression of Entera from an early stage R&D platform to a late stage clinical company with two core PTH programs in Phase 2/3 development and core R&D strategic partnerships, including with Amgen," said Mr.
   Entera Bio Outlines Pivotal Osteoporosis Trial, Names New CEO  2022/07/18 13:11:36 Benzinga
Following its End of Phase 2 Meeting with the FDA, Entera Bio Ltd (NASDAQ: ENTX ) has designed the pivotal study for EB613 as an 18-month double-blind placebo-controlled study, followed by a 6-month open-label transition to alendronate for all patients. The study''s primary endpoint employs the Foundation for the National Institutes of Health Bone Quality Program (FNIH BQP) total hip Bone Mineral Density (BMD) as a surrogate endpoint … Full story available on Benzinga.com
   Entera Bio Announces Departure of Dr. Phillip Schwartz, the Company’s President of Research & Development to Pursue Outside Opportunities  2022/06/17 21:00:00 GlobeNewswire
BOSTON and JERUSALEM, June 17, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, today announced that Dr. Phillip Schwartz, the Company’s President of Research & Development and Founder, will resign from his current role effective July 21, 2022 to pursue other opportunities. Dr. Schwartz also stepped down from the Company’s Board of Directors, effective June 15, 2022. Dr. Schwartz’s resignation was not a result of any disagreement with the Company and Dr. Schwartz will remain as a consultant to the Company.
   Entera Bio Announces Departure of Dr. Phillip Schwartz, the Company''s President of Research & Development to Pursue Outside Opportunities  2022/06/17 21:00:00 Benzinga
BOSTON and JERUSALEM, June 17, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX ), a leader in the development of orally delivered peptides and therapeutic proteins, today announced that Dr. Phillip Schwartz, the Company''s President of Research & Development and Founder, will resign from his current role effective July 21, 2022 to pursue other opportunities. Dr. Schwartz also stepped down from the Company''s Board of Directors, effective June 15, 2022. Dr. Schwartz''s resignation was not a result of any disagreement with the Company and Dr. Schwartz will remain as a consultant to the Company. Bringing in his expertise from various development and commercialization roles at Merck KGaA-Serono and Endo Pharmaceuticals, Dr. Schwartz was a co-founder of Entera Bio in 2009 and led the Company as Chief Executive Officer through 2019 and its IPO in 2018. "We are grateful for Phillip''s vision and leadership which have been paramount to the progression of Entera from an early stage R&D platform to a late stage clinical company with two core PTH programs in Phase 2/3 development and core R&D strategic partnerships, including with Amgen," said Mr.
   Entera Bio Ltd. (ENTX) CEO Spiros Jamas on Q1 2022 Results - Earnings Call Transcript  2022/05/18 18:34:07 Seeking Alpha
Entera Bio Ltd. (NASDAQ:NASDAQ:ENTX) Q1 2022 Earnings Conference Call May 17, 2022 08:00 ET Company Participants Spiros Jamas - Chief Executive Officer Miranda Toledano - Chief Business…
   Entera Bio GAAP EPS of -$0.13 beats by $0.05, revenue of $0.07M misses by $0.02M  2022/05/12 12:08:57 Seeking Alpha
Entera Bio press release (ENTX): Q1 GAAP EPS of -$0.13 beats by $0.05.Revenue of $0.07M (-56.3% Y/Y) misses by $0.02M.As of March 31, 2022, Entera had cash and cash equivalents of…
   Thinking about buying stock in Bridgeline Digital, Seelos Therapeutics, Vistagen Therapeutics, BioLineRx, or Entera Bio?  2021/07/01 12:30:00 Benzinga
NEW YORK , July 1, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BLIN, SEEL, VTGN, BLRX, and ENTX. Full story available on Benzinga.com
   Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613 Positioned to be the First Oral Bone-Building Agent for the Treatment of Osteoporosis  2021/06/28 19:15:00 Intrado Digital Media
BOSTON and JERUSALEM, June 28, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will conduct a conference call to discuss results from its successfully completed Phase 2 clinical trial of EB613 for the treatment of osteoporosis. EB613 is an oral formulation of human parathyroid hormone (1-34), or PTH, and is positioned to be the first oral bone building (anabolic) product to treat osteoporosis patients.
   Entera Stock Could More Than Double From Here, Says Analyst  2021/06/25 22:23:29 TipRanks
In the biotech space, big announcements often precede big share price movements; both were on tap for Entera Bio (ENTX) on Wednesday. Entera shares took off after the
   Stock with unusually volume activity: Entera Bio Ltd. (NASDAQ:ENTX), Fisker Inc. (NYSE:FSR)  2021/06/24 22:44:19 Stock Equity
Entera Bio Ltd. (NASDAQ:ENTX) with the stream of -6.31% also noticed, India Fisker Inc. (NYSE:FSR) encountered a rapid change of 0.70% in the last hour of Thursdays trading session. Entera The post Stock with unusually volume activity: Entera Bio Ltd. (NASDAQ:ENTX), Fisker Inc. (NYSE:FSR) appeared first on Stocks Equity .
   45 Biggest Movers From Yesterday  2021/06/24 09:08:28 Benzinga
Gainers Entera Bio Ltd. (NASDAQ: ENTX ) shares Full story available on Benzinga.com

calendar